Product Description
Levofloxacin is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain bacterial infections, such as community-acquired pneumonia, acute worsening of chronic bronchitis, anthrax, urinary tract infections, acute sinus infections, and others.
Community-acquired pneumonia, a bacterial respiratory infection, can be an opportunistic infection (OI) of HIV.
AI Product Description
*The following content is generated by AI and is for reference only.
Levofloxacin is a broad-spectrum fluoroquinolone antibiotic widely utilized in modern clinical practice for treating various bacterial infections. Its chemical identity is defined by the molecular formula C18H20FN3O4 and it is recognized globally under the CAS number 100986-85-4. As the active L-enantiomer of ofloxacin, levofloxacin exhibits superior potency with reduced toxicity compared to its racemic counterpart. The molecule functions primarily by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes required for DNA replication, transcription, repair, and recombination. This mechanism effectively halts bacterial cell division, leading to rapid bactericidal activity against a diverse range of pathogens.
Clinically, levofloxacin is indicated for the treatment of respiratory tract infections, including community-acquired pneumonia, acute bacterial sinusitis, and exacerbations of chronic bronchitis. It is also highly effective against urinary tract infections, pyelonephritis, prostatitis, and skin or soft tissue infections caused by susceptible organisms such as Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, and Staphylococcus aureus. Due to its excellent bioavailability and favorable pharmacokinetic profile, it can be administered orally or intravenously, allowing for flexible treatment protocols that facilitate early hospital discharge. The drug demonstrates good tissue penetration, reaching therapeutic concentrations in lungs, kidneys, and prostatic fluid.
Despite its efficacy, the use of levofloxacin requires careful consideration due to potential adverse effects, including tendonitis, tendon rupture, peripheral neuropathy, and central nervous system disturbances. Regulatory agencies often advise reserving fluoroquinolones for cases where alternative antibiotics are unsuitable to mitigate the risk of promoting antimicrobial resistance. Furthermore, contraindications include patients with a history of hypersensitivity to quinolones or those with known QT interval prolongation. Ongoing research continues to explore novel formulations and combination therapies to enhance its therapeutic index while minimizing side effects. Overall, levofloxacin remains a cornerstone agent in combating multidrug-resistant bacterial infections, provided it is prescribed judiciously within established clinical guidelines to ensure patient safety and public health preservation.